CarciScan DNA helix visual
Investor Overview · Raising USD 5–7M

Early cervical
cancer detection,
built for the last mile.

CarciScan is an at-home HPV self-test bringing screening to the 22.2M Filipino women who never make it to a clinic. Backed by a positive HTA Council financing recommendation and a growing international evidence base.

View the ask See the evidence
PH HTA Council — Positive Recommendation Karolinska / WHO Reference Center eDNA Teknoloji · Türkiye Ghana Protocol · Cancer Control 2025 PH HTA Council — Positive Recommendation Karolinska / WHO Reference Center eDNA Teknoloji · Türkiye Ghana Protocol · Cancer Control 2025
The Opportunity

Cervical cancer is preventable. Access isn't the problem — reach is.

The Philippines has 22.2 million women eligible for screening, most of whom are priced or distanced out of clinic-based Pap smears. CarciScan turns that gap into an addressable market.

22.2M
Eligible women in the Philippines
₱8.9–11.1B
Annual addressable pool at ₱2,000–2,500 per test
vs. ₱5,000–8,000 for incumbent clinic-based testing
Mar 2025
PH HTA Council issued a positive government-financing recommendation
The strongest policy signal to date
Evidence, Reviewed Honestly

What the data supports — and what it doesn't, yet.

We present this evidence the way it would survive due diligence: real studies, real caveats, no inflated volumes.

Feb 2026

Karolinska / WHO Reference Center collaborative study Preprint

Dillner et al., medRxiv, 4 Feb 2026 — a 10-country, 13-assay evaluation in which a Turkish reference lab used CarciScan as its assay. Pooled results across all assays: 90.08% sensitivity / 92% specificity.

Caveat: results are pooled across assays with no CarciScan-specific breakout, and the paper is a preprint — not yet peer-reviewed.
2025

Ghana screening protocol Peer-reviewed

Taumberger et al., Cancer Control (SAGE), 2025 — a published, peer-reviewed protocol for an n=1,000 study using CarciScan as the assay.

Caveat: this is the study protocol only. Interim results are expected ~Jan 2026; the full study concludes in 2029.
Jul 2026

Prof. Murat Gültekin — KOL endorsement

Letter from Hacettepe University (6 Jul 2026) supporting a Philippines pilot / proof-of-concept, from a globally recognized cervical-screening authority and co-author on the Karolinska/WHO study.

Context

Turkey demonstrates national-scale feasibility

Turkey's national program has screened roughly 4.1M women using HPV DNA testing at scale — evidence that population-level HPV self/self-collect screening works operationally in a comparable health system.

We deliberately do not claim that CarciScan itself screened this volume in Turkey — the product-specific figure is unverified. What's supportable is program-level feasibility, and it's exactly what we present to investors.

Full clinical detail on the product page →

Leadership

A team built around logistics, clinical credibility, and local reach.

Malaya United is led by President/CEO Ace John Oliver Vollbrecht, with a board spanning logistics, community health, and international advisory experience, plus a management bench covering technology, finance, and sales execution.

Warehousing & Logistics Social Impact Corporate & Legal Technology

See full leadership & partners →

CarciScan test kit
The Ask

Raising USD 5–7M to scale distribution and deepen the clinical record.

Proceeds are earmarked toward LTO completion and regulatory operations, distribution & logistics scale-up, and continued clinical/RWE investment alongside our Ghana and Turkey partners.

01

Regulatory & Ops

Complete License to Operate (LTO) as a medical-device establishment — the Philippines does not require FDA product approval for this device class.

02

Distribution

Scale last-mile logistics and community access channels to convert the 22.2M-woman addressable population into screened patients.

03

Clinical Record

Fund continued participation in the Ghana study and pursue CarciScan-specific breakout data alongside the Karolinska/WHO collaboration.

Request the full data room →